GlassScriptPhysician profile
Maria Baens
NPI 1447256672
$1,496.99
in general payments reported to CMS, 2019-2025
21 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $671 · 2024: $371 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,497.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,496.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $500.56 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $242.16 | 2023-2025 | Farxiga, Airsupra |
| Abbvie INC. | $128.90 | 2023-2025 | Vraylar |
| Exact Sciences Corporation | $74.40 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $68.51 | 2024-2025 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $52.24 | 2023-2024 | Injectafer |
| Hologic Sales and Service, LLC | $44.69 | 2023 | Aptima, Thinprep 2000 Processor |
| Xeris Pharmaceuticals, INC. | $43.74 | 2023-2025 | Gvoke Hypopen |
| Lilly USA, LLC | $43.59 | 2024-2025 | Mounjaro, Zepbound |
| Mylan Specialty L.P. | $39.98 | 2023 | Yupelri |
| Glaxosmithkline, LLC. | $36.60 | 2024-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.49 | 2023-2025 | Xifaxan, Trulance |
| Amgen INC. | $32.08 | 2024-2025 | Otezla, Repatha, Repatha |
| Dexcom, INC. | $29.97 | 2025 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $27.52 | 2024 | Gemtesa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $21.65 | 2024 | Rexulti |
| Nevro Corp. | $18.50 | 2023 | Senza |
| Sanofi-Aventis U.S. LLC | $18.25 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $14.41 | 2023 | Eliquis |
| Astellas Pharma US INC | $12.91 | 2023 | Veozah |
| Idorsia Pharmaceuticals US INC | $12.84 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Baens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.